Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

82.10 +1.80 (+2.24%)
Streaming Delayed Price Updated: 11:06 AM EDT, Aug 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,665,503
Open 80.75
Bid (Size) 82.09 (1)
Ask (Size) 82.10 (5)
Prev. Close 80.30
Today's Range 80.20 - 82.51
52wk Range 73.31 - 120.30
Shares Outstanding 2,531,374,696
Dividend Yield 3.95%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
If You're In Your 20's, Consider Buying These 3 Healthcare Stocks
If you have decades to go before you retire, you want to make sure you own companies that know how to survive and thrive. 
Via The Motley Fool
Topics Retirement
MRK Q2 Deep Dive: Pipeline Strength and New Product Launches Highlight Transition Period
Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% year on year to $15.81 billion. The company’s outlook for the full year was... 
Via StockStory

Performance

YTD
-17.2%
-17.2%
1 Month
-1.9%
-1.9%
3 Month
+7.1%
+7.1%
6 Month
-5.1%
-5.1%
1 Year
-27.7%
-27.7%

More News

Read More
Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients
Via Benzinga
KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
From Merck & Co., Inc.
Via Business Wire
3 Reasons We’re Fans of Merck (MRK)
Via StockStory
Topics Stocks Supply Chain
IO Biotech Stock Slumps After Trial Of Cancer Therapy Plus Keytruda Misses Study Goal: Retail Sees Shares Rise 10x
Via Stocktwits
IO Biotech's Combo Therapy For Skin Cancer Falls Just Short, Eyes FDA Talks Later This Year
Via Benzinga
2 Magnificent Stocks to Buy That Are Near 52-Week Lows
Via The Motley Fool
Topics Intellectual Property
3 High-Yield Healthcare Stocks to Buy Hand Over Fist in August
Via The Motley Fool
Topics Economy Intellectual Property
2 Cash-Producing Stocks for Long-Term Investors and 1 We Brush Off
Via StockStory
Political Tremors Rattle Markets: The Profound Impact of U.S. Elections and Tariff Shocks
Via MarketMinute
Topics Economy Government Stocks
Is It Time to Buy Biotech Stocks?
Via The Motley Fool
MERCK & CO. INC. (NYSE:MRK): A Top Dividend Stock with Strong Profitability and Financial Stability
Via Chartmill
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks World Trade
Merck (MRK) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
Via Investor Brand Network
Topics Government
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas
Via FinancialNewsMedia
Topics Government
This Biotech Stock Could Soar on Upcoming Clinical Data
Via The Motley Fool
Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
3 High-Yielding Dividend Stocks That Are Trading Near Their 52-Week Lows
Via The Motley Fool
Topics Intellectual Property
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...'
Via Benzinga
Topics Government
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
Investing $2,000 in Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth Nearly $135,000 Today
Via The Motley Fool
Topics Artificial Intelligence
Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns
Via Benzinga
Topics Earnings
Why Merck Stock Slipped Today
Via The Motley Fool

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 82.10
When was Merck & Co last traded?
The last trade of Merck & Co was at 08/13/25 11:06 AM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 207.83B
How many shares of Merck & Co are outstanding?
Merck & Co has 208B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.